Google
RVTY Stock Analysis — REVVITY INC. (Healthcare >> Diagnostics & Research)
RVTY FAQ
What is RVTY's P/E ratio?
REVVITY INC. (RVTY) currently trades at a P/E ratio of 52.57.
What is RVTY's ROE?
REVVITY INC. reports a Return on Equity (ROE) of 3.35%.
What is RVTY's dividend yield?
REVVITY INC. offers a dividend yield of 0.25%.
What is RVTY's Quality Score?
Our AI rates RVTY's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy RVTY?
Our AI Timing Score for RVTY is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does RVTY belong to?
REVVITY INC. is classified under the Healthcare >> Diagnostics & Research sector on the NYSE exchange
RVTY AI Analysis Summary
Our AI summary for RVTY: REVVITY INC. (NYSE), Healthcare >> Diagnostics & Research sector. The stock currently trades at a P/E of 52.57, ROE of 3.35%, a dividend yield of 0.25%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 112.52
Price
-1.02
(-0.90%)
Day Change
|
|
|---|
RVTY, the overall quality is not good ( Quality = 46) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Quality Factors |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
2804
|
| Magic Formula Rank by ROE |
2804
|
| Magic Formula Rank by ROIC |
2897
|
| Price | 112.52 |
| PBV / Sector |
1.76 / -29.69
|
| Earning Per Share | 2.14 |
| PE / Sector |
52.57 / 48.18
|
| PEG or PE/Growth / Sector |
-0.32 / 1.64
|
| Average 1M Daily Value |
127.41 M
GREAT
|
| Average 1W Daily Value |
167.21 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
52% |
| Ability to Make Profit |
|
54% |
| Return to Investors |
|
41% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:26 |
| Symbol | RVTY |
| Name | REVVITY INC. |
| Sector | Healthcare >> Diagnostics & Research |
| Market | NYSE |
| Listed Shares | 111.56 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 12,666.50 / 38,081.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 77 4th Avenue, Waltham, MA, United States, 02451
Phone: 781 663 6900
Website: https://www.revvity.com
Employees: 11,000
Description: Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Diagnostics & Research
Click a bubble to view stock details · Bubble size represents market capitalization share
